Dermata Opens a New Chapter with the Release of Tome Skincare
SAN DIEGO, CA / March 5, 2026 / Dermata Therapeutics, Inc. (Nasdaq:DRMA)(Nasdaq:DRMAW) ("Dermata" or the "Company"), a science-driven leader in dermatologic solutions, today proudly announces the branding of its latest innovation in skincare: Tome, which aims to introduce "skintech at home". The Company's Tome skincare line will bring intentionally developed skincare that delivers a high level of efficacy by addressing the root causes of skin diseases and conditions. Tome is Studied Skincare™, utilizing timeless ingredients with modern innovations for today's curious skincare consumer. Dermata believes there is immense market opportunity to offer all-natural, multi-action, high-performing skincare treatments directly to consumers for a professional aesthetician feel at home.
"With Tome, our mission is to forge a new realm of skincare that is powerful, not punishing," commented Gerry Proehl, Dermata's Chief Executive Officer. "We plan to offer products that are studied by dermatologists but accessible to consumers without the need for a prescription. We intend to prioritize products with natural and safe ingredients that deliver prescription-like results. We believe our products will have heightened potency that never comes at the expense of health and wellbeing of our customers," Mr. Proehl continued. "In a world filled with treatments that complicate routines, over-promise, and underdeliver, Tome exists to be the new foundation of any well-rounded skincare routine. We aren't here to find balance or compromise between existing approaches to skincare, we are melding ancestral wisdom with scientific innovation to create an entirely new ritual for our customers," Mr. Proehl concluded.
This announcement marks a significant milestone in the Company's strategic evolution and long-term growth roadmap to become a consumer-facing company specifically tailored to meet the evolving needs of today's skincare consumers. The Tome skincare line will emphasize products Dermata believes can become the essential foundation of any well-rounded skincare routine. In a category full of complex ingredients and daily routines, Tome intends to return to the time-tested remedies with simple but effective weekly routines. While first targeting the launch of an over the counter, once-weekly acne and resurfacing treatment in mid-2026, Dermata believes its Tome product line will become part of an essential foundation for enhancing overall skin quality and beauty.
About Tome
Tome is Dermata's newest skincare line to bring about a new realm of skincare that is powerful, not punishing. Tome in its literal meaning is a large, important, scholarly book, usually telegraphing ancestral innovations. Dermata intends to educate consumers with a brand that tells a story while being rooted in science and history. Tome will consist of a line of skincare products made with
About Dermata Therapeutics
Dermata Therapeutics is a scientific leader in dermatology that recently announced a strategic pivot from pharmaceutical development to begin focusing on the development and distribution of direct-to-consumer skincare solutions. The Company is currently developing a once-weekly acne treatment system that utilizes an active ingredient from US Food and Drug Administration over-the-counter monograph in combination with Dermata's
Dermata Investors:
Cliff Mastricola
Investor Relations
[email protected]
SOURCE: Dermata Therapeutics
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Japanese Fintech Goes Live On XRP Ledger As ETFs Climb
Oracle plans thousands of job cuts as data center costs rise, Bloomberg News reports
Earnings Estimates Rising for Credo Technology Group (CRDO): Will It Gain?

AEO Faces Market Pressure As Analysts Weigh Marketing Costs
